Spotlight LEADERSLEADERS 5-Year Results presented at TCTFinal results from the groundbreaking LEADERS study were presented during TCT 2012. LEADERS was the first head-to-head randomized clinical study (RCT) between two limus-eluting stents, the first RCT between two stents to involve an "all-comers" patient population, and the first to be independently monitored and assessed by its investigators.
Axxess™Axxess™ - Self-expanding bifurcation DES, is Biosensors’ dedicated bifurcation DES The device is the first BA9™-eluting dedicated bifurcation stent, complementing the existing BioMatrix family of product. It features our PLA/BA9™ technology, with an abluminal* biodegradable coating.
* The coating is applied primarily on the abluminal surface.